We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Micap | MIC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.375 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.375 | 0.375 |
| Top Posts |
|---|
Posted at 31/7/2008 18:09 by trixter Does this look like an extension/developmenAIMHO etc. |
Posted at 26/9/2007 07:42 by trixter Perhaps they are waiting for Mr Mapstone to get back from a round the world cruise or he's too pre-occupied fixing Hill Station...! Let's hope MIC are not another HLL! |
Posted at 18/9/2007 10:45 by trixter On the iii MIC board today there is speculation about the possible link between MIC and MDX (BPRG)."Quite possible with the Meldex (Bioprogress) tie up. Its old (2004) but these things take time. I actually believe the results will show a marked improvement." Anyone know the latest on this? MDX release results on 25/9. Wonder if MIC will release the same day? The chances narrow with every day that passes... I hold MIC. IMO, DYOR etc... |
Posted at 31/7/2007 14:15 by don muang well, it did seem like a good idea to hold MIC until this week.... but if good news comes with next RNS then .... |
Posted at 27/7/2007 15:21 by mikehardman Don - good to see you hereindifference persists... a 70-bagger would be so nice... reminder from 19dec06 interims: 'We are now generating revenues from all our operating divisions, with significant growth expected from Micap Encapsulates in the next few months. The extension to the Nufarm option agreement will make the achievement of a break even position in the final quarter unlikely, but if we continue to make the progress we are seeing throughout the Group this should be possible early in our new financial year.' the finals must be imminent... I live in hope! hope of another AUK, NOP, KMR, etc. - all of which were dogs in their day and yer gotta have the odd dog in the portfolio, else you're not gonna get one of them bagger-in-a-day pops that occur now and then :) |
Posted at 30/5/2007 21:19 by don muang ... & presumably obliviation for those that don't ...still 'presuming' that MIC will 'have the right product'. |
Posted at 24/4/2007 12:37 by mikehardman long a few ~1.8p;bid ticked up 19dec06 interims - turnover +146%, losses down, getting there, expects profitable next FY "We are now generating revenues from all our operating divisions, with significant growth expected from Micap Encapsulates in the next few months." finals are in June, but I'm kinda hoping we'll get a trading stmt before then (had one 6apr in 2006), hopefully proving that 'significant growth'. |
Posted at 06/4/2005 07:07 by pomp circumstance At last!!!!MICAP PLC 06 April 2005 6th April 2005 SKYEPHARMA NOMINATES PRODUCTS FURTHER TO EXERCISE OF OPTION AND TRADING UPDATE Micap plc (LSE: MIC), the technology licensing company specialising in the microencapsulation of active ingredients in yeast cells, today announces that SkyePharma plc (LSE: SKP, Nasdaq: SKYE) will incorporate Micap's yeast-based delivery system in its ongoing development of a further nine (9) pharmaceutical products. This announcement completes SkyePharma's current option agreement with Micap. In March 2004, SkyePharma exercised an option to acquire an exclusive licence to use Micap's patented microencapsulation technology. This allowed SkyePharma to use Micap's technology for the delivery of hydrophobic drugs in up to ten nominated pharmaceutical products ('Option Products') to be selected by SkyePharma and in August 2004 the first Option Product was nominated. SkyePharma has, since the first Option Product was nominated, been evaluating a number of other potential Option Products, using its experience of drug delivery technologies to identify those compounds most suitable for the Micap technology and with the greatest market opportunity and has now nominated the remaining nine (9) Option Products. Whilst the identity of these products cannot be disclosed for reasons of commercial confidentiality, they are all oral doseage forms and include a combination of proprietary and generic compounds. Under the terms of the March 2004 agreement, royalties will be payable by SkyePharma to Micap on sales made of, or licences granted on, any Option Product. SkyePharma will also make milestone payments on the successful completion of Phase II and Phase III clinical trials and also on the commercial launch of the first Option Product. Micap will now carry out an optimisation program on the encapsulated compounds and SkyePharma will undertake formulation and stability studies with a view to commencement of further pre-clinical trials. Micap continues to be in discussions with a number of partners regarding evaluation, development and licensing deals and hopes to be in a position to inform shareholders of further progress on these negotiations soon. These discussions have been progressing well, however, in some cases they have taken longer than expected to conclude and whilst costs remain in line with management's expectations, certain access and option fees anticipated to be received in the financial year to 31 March 2005 will now fall due in the new financial year. The Board is pleased with the significant progress in both the quality and number of Micap's partnerships and look forward to positive developments in the coming months. Michael Brennand, Chief Executive of Micap, said: 'The nomination by SkyePharma of their remaining Option Products is a significant milestone for Micap. Not only are we moving to the next stage of development with a world leading drug-delivery company, but the conclusion of the Option agreement with SkyePharma allows us to actively market our patented encapsulation system to other companies within the pharmaceutical market. We are particularly excited about our opportunity in relation to topical skin applications of products, where we have recently experienced highly positive results in laboratory trials.' For further information please contact: Contact: Micap plc +44 (0)1925 664200 Michael Brennand, CEO +44 (0)7966 341801 Michael Norris, CFO +44 (0)7966 341802 Binns & C PR +44 (0)20 7786 9600 Tarquin Edwards/Chris Steele 07879 458 364 / 07979 604 687 |
Posted at 20/10/2004 07:42 by m.t.glass "...Discussions are currently underway with a major multinational..." MICAP PLC 20 October 2004 Micap plc 20th October 2004 Micap plc announces positive results of a recent study on use of Micap encapsulated fungicides to improve control of fungal damage to cereal crops. Micap plc ('Micap', LSE: MIC) today announces new business opportunities in the area of agrochemicals. Further to the recently-reported success in the evaluation of Micap technology for herbicides, promising new results have now been obtained in fungicide applications. Micap has funded laboratory trials at the University of Nottingham comparing the performance of a commercial fungicide formulation with a formulation based on Micap technology. The target for the study was the ear blight fungus Fusarium, which represents a significant commercial threat to cereal farmers. The outcome of the study showed that a standard Micap formulation performed well compared to a commercial product for stem based disease control. Additionally, in mature plants, when wheat ears were infected, the Micap formulation of the fungicide tebuconazole outperformed the commercial product, resulting in an increased grain yield. In addition, subsequent studies have demonstrated a substantial reduction in the levels of Fusarium mycotoxin present in the grain of Micap-treated plants. This is a likely reflection of the benefit of sustained release of the active ingredient. The use of the Micap encapsulation technology for the delivery of fungicides offers the potential to control mycotoxin contamination of grain to below 0.75ppm, the target level currently under review by the European Union. Michael Brennand, Chief Executive of Micap, said: 'We are delighted at these encouraging study results and look forward to the continued development of fungicidal applications.' Dr. Steve Rossall, senior lecturer in plant pathology at Nottingham University, commented: 'The results produced by the Micap technology in the Fusarium study were very promising, particularly since the formulation of the Micap product had not been optimised.' Discussions are currently underway with a major multinational to carry out field trials incorporating the Micap formulation of tebuconazole used in the study. Ongoing studies include the evaluation of Micap formulations of a number of azole fungicides against their commercial equivalents, whilst trials of seed dressing applications are currently at the planning stage. Contact: Micap plc 01925 664200 Michael Brennand, CEO 07966 341801 Michael Norris, Finance Director 07966 341802 Gavin Anderson & Company 020 7554 1400 Janine Brewis About Micap Micap listed on AIM in August 2003 and is a UK technology licensing company specialising in the micro encapsulation of active ingredients within yeast cells. For further details visit www.micap.co.uk . Micro encapsulation is a process whereby tiny droplets of liquid or particles of solid material are coated with a continuous film of polymeric material. Microcapsules have several benefits, including conversion of liquids to solids; separating reactive compounds; protecting substances against environmental factors; and improving the material handling properties. Micap's unique proprietary technology involves using killed yeast cells as natural capsules to protect the active ingredient. Yeast encapsulation can protect active ingredients against high temperatures, the effects of the sun, pressure and degradation through exposure to the air. The natural affinity of yeast cells for mucous membranes can also be exploited for targeted drug delivery. About Fusarium blight The global market for agrochemicals is around $30bn and is split into three main sectors: herbicides, fungicides and insecticides. Fusarium is a stem-based pathogen of cereals which primarily affects the ears, causing reduced yield and importantly a contamination of the grain with mycotoxins, which are potentially harmful to people. Fusarium Ear Blight infection was estimated to cause a loss in excess of $2.5bn to farmers in the US between 1998-2000 (Ngenje et al, Oct 2001). Mycotoxins Mycotoxins are toxic chemicals produced by moulds growing on food commodities or animal feedstuffs. In order to protect public health, they are subject to government regulation in most countries. This information is provided by RNS The company news service from the London Stock Exchange |
Posted at 17/8/2004 07:11 by bigboony MICAP PLC17 August 2004 17 August, 2004 SKYEPHARMA EXERCISES OPTION UNDER AGREEMENT WITH MICAP Micap plc (LSE: MIC), the technology licensing company specialising in the microencapsulation of active ingredients in yeast cells, today announces that SkyePharma plc (LSE: SKP, Nasdaq: SKYE) has decided to exercise its option to select for further development a number of pharmaceutical products that incorporate Micap's yeast-based delivery system. In March 2004, SkyePharma exercised an option to acquire an exclusive licence to use Micap's patented microencapsulation technology. This allows SkyePharma to use Micap's technology for the delivery of hydrophobic drugs in up to ten nominated pharmaceutical products ('Option Products') to be selected by SkyePharma. SkyePharma has subsequently been evaluating a number of potential Option Products and is now in a position to nominate the first Option Product. The identity of this product has not been disclosed for reasons of commercial confidentiality. SkyePharma will continue to review additional product opportunities, and expects to make further nominations prior to the expiry of the Option Period. Under the terms of the March agreement, ongoing royalties will be payable by SkyePharma to Micap on sales made, or licences of, any Option Product. SkyePharma will also make milestone payments on the first successful completion of Phase II and Phase III clinical trials and also on the first commercial launch of an Option Product. Michael Brennand, Chief Executive of Micap, said: 'The commitment shown by SkyePharma is a major validation of the potential applications of our microencapsulation technology in the pharmaceutical area. We look forward to progressing the relationship through clinical trials and product launches.' Michael Ashton, Chief Executive of SkyePharma, said: 'We continue to be pleased with our relationship with Micap. In January 2003, we agreed to evaluate the application of the Micap microencapsulation technology to the delivery of hydrophobic drugs. Following pre-clinical evaluation of the Micap technology in both oral and topical drug delivery applications, we decided to exercise our option in March this year. We are now able to report that we have selected the first Option Product for further development. We will continue to evaluate other candidate Option Products, which we must nominate by the end of March 2005. The Micap technology further expands our growing range of drug delivery options.' For further information please contact: Contact: Micap plc +44 (0)1925 664200 Michael Brennand, CEO +44 (0)7966 341801 Gavin Anderson & Company (For Micap) +44 (0)20 7554 1400 Liz Morley/Janine Brewis/Tom Siveyer SkyePharma plc +44 (0)20 7491 1777 Michael Ashton, CEO Peter Laing, Director of Corporate Communications +44 (0)20 7491 5124 Notes for editors: About Micap Micap is a UK technology licensing company specialising in the microencapsulation of active ingredients within yeast cells. For further details visit www.micap.co.uk . About SkyePharma SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now ten approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www.skyepharma.com . About microencapsulation Microencapsulation is a process whereby tiny droplets of liquid or particles of solid material are coated with a continuous film of polymeric material. Microcapsules have several benefits, including conversion of liquids to solids; separating reactive compounds; protecting substances against environmental factors; and improving the material handling properties. Micap's unique proprietary technology involves using killed yeast cells as natural capsules to protect the active ingredient. Yeast encapsulation can protect active ingredients against high temperatures, the effects of the sun, pressure and degradation through exposure to the air. The natural affinity of yeast cells for mucous membranes can also be exploited for targeted drug delivery. About hydrophobic drugs Certain pharmaceuticals dissolve readily in oils or organic solvents but are wholly or partially insoluble in water. These hydrophobic drugs pose particular delivery problems since, in order to be properly absorbed by the body, nearly all drugs need to dissolve in water. This information is provided by RNS The company news service from the London Stock Exchange |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
